Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206206 · ClinicalTrials.gov registry record · NA
Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart
A NA study, sponsored by Atlantic Health System.
- Terminated
- Registry status
- NA
- Development phase
- 235
- Enrollment target
NCT00206206 is a NA study that was terminated before completion, run by Atlantic Health System. The registered enrollment target is 235 participants.
The verdict
NCT00206206, a NA study, was terminated before completion, sponsored by Atlantic Health System.
- TERMINATED
- Registry status
- NA
- Development phase
- 235 participants
- Enrollment target
Study Summary
In response to the evidence supporting "tight" glucose control (70 - 110) in the critical care setting, the MMH ICU developed a protocol utilizing regular intravenous insulin. This protocol was initiated in 2002. Monitoring of the data collected revealed effective glycemic control when this protocol was used. However, limited utilization has led to overall ineffective glycemic control in this ICU. The poor utilization is largely due to a general reluctance of physicians to start their patients on an intravenous insulin infusion. As contributing to this poor compliance is the "open" nature of the ICU. The MMH ICU is an "open" ICU, meaning that many physicians across multiple subspecialties admit to this unit. Approaches to controlling hyperglycemia vary greatly, depending largely upon the treating physician. In an attempt to improve overall glycemic control in this "open" ICU, the Subcutaneaous Insulin Aspart Hyperglycemia Protocol (SIAP) was developed which incorporates a subcutaneous insulin aspart regimen that triggers the use of a regular insulin infusion protocol when the SIAP is not adequately controlling the patient's blood glucose. This study aims to evaluate 1) the effect the SIAP on overall glycemic control in the ICU, 2) the effectiveness that the SIAP has on controlling blood glucose as compared with past practices using regular insulin, and 3) the effect the SIAP has on patient complications and outcomes in the MMH ICU.
Interventions
- PROCEDURE Hyperglycemia Protocol Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2005-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206206
The ClinicalTrials.gov registry entry for NCT00206206 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atlantic Health System, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperglycemia Protocol Procedure is the first listed.
NCT00206206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206206 about?
NCT00206206 is a clinical study titled "Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart". In response to the evidence supporting "tight" glucose control (70 - 110) in the critical care setting, the MMH ICU developed a protocol utilizing regular intravenous insulin. This protocol was initiated in 2002. Monitoring of the data collected revealed effective glycemic control when this protocol...
What is the current status of trial NCT00206206?
This trial is currently terminated. It is a NA study. The enrollment target is 235 participants. The study started on 2005-07.
What interventions are being tested in trial NCT00206206?
The interventions under investigation include: Hyperglycemia Protocol Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT00206206?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.